Advertisement

Clostridium difficile-Associated Diseases

  • C. S. Pitchumoni
  • C. S. Pitchumoni
  • C. S. Pitchumoni
  • T. S. Dharmarajan
  • T. S. Dharmarajan
  • T. S. Dharmarajan
  • T. S. Dharmarajan
Chapter

Abstract

Clostridium difficile is the most common and important cause of healthcare infection, manifesting as a spectrum of disease ranging from mild diarrhea to toxic megacolon and pseudomembranous colitis. The causative organism, an anaerobic spore-forming bacillus, particularly affects people who have received antibiotics in the recent past; additional predispositions besides older age include immune suppressed states, gastric surgery, tube feeding, and chronic kidney disease. The geriatric population is vulnerable to complications and mortality. A variety of stool assays help in diagnosis. Prevention is the key, with infection control measures and meticulous hand hygiene important. Initial therapy includes use of metronidazole or vancomycin. Resistance and recurrence are handled differently. Newer drugs, monoclonal antibodies, and vaccines may offer better options in future.

Keywords

Chronic Kidney Disease Inflammatory Bowel Disease Irritable Bowel Syndrome Infection Control Measure Oral Vancomycin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Bartlett JG. Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism. Clin Infect Dis. 1994;18 Suppl 4:S265–72.PubMedCrossRefGoogle Scholar
  2. 2.
    Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 1997;92:739–50.PubMedGoogle Scholar
  3. 3.
    Tedesco FJ, Barton RW, Alpers DH. Clindamycin-associated colitis. A prospective study. Ann Intern Med. 1974;81:429–33.PubMedGoogle Scholar
  4. 4.
    Thomas C, Stevenson M, Riley TV. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother. 2003;51:1339–50.PubMedCrossRefGoogle Scholar
  5. 5.
    Surawicz CM. Treatment of recurrent Clostridium difficile-associated disease. Nat Clin Pract Gastroenterol Hepatol. 2004;1:32–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Thomas C, Riley TV. Restriction of third generation cephalosporin use reduces the incidence of Clostridium difficile-associated diarrhoea in hospitalised patients. Commun Dis Intell. 2003;27(Suppl):S28–31.PubMedGoogle Scholar
  7. 7.
    Aslam S, Musher DM. An update on diagnosis, treatment, and prevention of Clostridium difficile-associated disease. Gastroenterol Clin North Am. 2006;35:315–35.PubMedCrossRefGoogle Scholar
  8. 8.
    Ananthakrishnan AN, Guzman-Perez R, Gainer V, et al. Predictors of severe outcomes associated with Clostridium difficile infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35(7):789–95.Google Scholar
  9. 9.
    Bartlett JG. Historical perspectives on studies of Clostridium difficile and C. difficile infection. Clin Infect Dis. 2008;46 Suppl 1:S4–11.PubMedCrossRefGoogle Scholar
  10. 10.
    Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis. 2008;46 Suppl 1:S12–8.PubMedCrossRefGoogle Scholar
  11. 11.
    McFarland LV. Update on the changing epidemiology of Clostridium difficile-associated disease. Nat Clin Pract Gastroenterol Hepatol. 2008;5:40–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Kuipers EJ, Surawicz CM. Clostridium difficile infection. Lancet. 2008;371:1486–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004;171:466–72.PubMedCrossRefGoogle Scholar
  14. 14.
    Lai KK, Melvin ZS, Menard MJ, et al. Clostridium difficile-associated diarrhea: epidemiology, risk factors, and infection control. Infect Control Hosp Epidemiol. 1997;18:628–32.PubMedCrossRefGoogle Scholar
  15. 15.
    Archibald LK, Banerjee SN, Jarvis WR. Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987–2001. J Infect Dis. 2004;189:1585–9.PubMedCrossRefGoogle Scholar
  16. 16.
    McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433–41.PubMedCrossRefGoogle Scholar
  17. 17.
    Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353:2442–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Moshkowitz M, Ben-Baruch E, Kline Z, et al. Risk factors for severity and relapse of pseudomembranous colitis in an elderly population. Colorectal Dis. 2007;9:173–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis. 2004;38:640–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Zheng L, Keller SF, Lyerly DM, et al. Multicenter evaluation of a new screening test that detects Clostridium difficile in fecal specimens. J Clin Microbiol. 2004;42:3837–40.PubMedCrossRefGoogle Scholar
  21. 21.
    Riegler M, Sedivy R, Pothoulakis C, et al. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest. 1995;95:2004–11.PubMedCrossRefGoogle Scholar
  22. 22.
    Leffler DA, Lamont JT. Treatment of Clostridium difficile-associated disease. Gastroenterology. 2009;136:1899–912.PubMedCrossRefGoogle Scholar
  23. 23.
    Surawicz CM. Antibiotics and Clostridium difficile: cause and cure. J Clin Gastroenterol. 2007;41:1–2.PubMedCrossRefGoogle Scholar
  24. 24.
    Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41:1254–60.PubMedCrossRefGoogle Scholar
  25. 25.
    Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ. 2005;173:1037–42.PubMedCrossRefGoogle Scholar
  26. 26.
    Dial S, Alrasadi K, Manoukian C, et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ. 2004;171:33–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Dial S, Delaney JA, Barkun AN, et al. Use of gastric acid-­suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294:2989–95.PubMedCrossRefGoogle Scholar
  28. 28.
    Dial S, Delaney JA, Schneider V, et al. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ. 2006;175:745–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999–2004. Emerg Infect Dis. 2007;13:1417–9.PubMedGoogle Scholar
  30. 30.
    Cohen SH, Tang YJ, Silva Jr J. Analysis of the pathogenicity locus in Clostridium difficile strains. J Infect Dis. 2000;181:659–63.PubMedCrossRefGoogle Scholar
  31. 31.
    Brazier JS, Stubbs SL, Duerden BI. Prevalence of toxin A negative/B positive Clostridium difficile strains. J Hosp Infect. 1999;42:248–9.PubMedGoogle Scholar
  32. 32.
    Drudy D, Harnedy N, Fanning S, et al. Isolation and characterisation of toxin A-negative, toxin B-positive Clostridium difficile in Dublin, Ireland. Clin Microbiol Infect. 2007;13:298–304.PubMedCrossRefGoogle Scholar
  33. 33.
    Geric B, Rupnik M, Gerding DN, et al. Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital. J Med Microbiol. 2004;53:887–94.PubMedCrossRefGoogle Scholar
  34. 34.
    Goncalves C, Decre D, Barbut F, et al. Prevalence and characterization of a binary toxin (actin-specific ADP-ribosyltransferase) from Clostridium difficile. J Clin Microbiol. 2004;42:1933–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Impallomeni M, Galletly NP, Wort SJ, et al. Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime. BMJ. 1995;311:1345–6.PubMedCrossRefGoogle Scholar
  36. 36.
    O’Connor D, Hynes P, Cormican M, et al. Evaluation of methods for detection of toxins in specimens of feces submitted for diagnosis of Clostridium difficile-associated diarrhea. J Clin Microbiol. 2001;39:2846–9.PubMedCrossRefGoogle Scholar
  37. 37.
    McFarland LV, Beneda HW, Clarridge JE, et al. Implications of the changing face of Clostridium difficile disease for health care practitioners. Am J Infect Control. 2007;35:237–53.PubMedCrossRefGoogle Scholar
  38. 38.
    Peterson LR, Manson RU, Paule SM, et al. Detection of toxigenic Clostridium difficile in stool samples by real-time polymerase chain reaction for the diagnosis of C. difficile-associated diarrhea. Clin Infect Dis. 2007;45:1152–60.PubMedCrossRefGoogle Scholar
  39. 39.
    Johal SS, Hammond J, Solomon K, et al. Clostridium difficile associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy. Gut. 2004;53:673–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Gerding DN, Muto CA, Owens Jr RC. Treatment of Clostridium difficile infection. Clin Infect Dis. 2008;46 Suppl 1:S32–42.PubMedCrossRefGoogle Scholar
  41. 41.
    McMullen KM, Zack J, Coopersmith CM, et al. Use of hypochlorite solution to decrease rates of Clostridium difficile-associated diarrhea. Infect Control Hosp Epidemiol. 2007;28:205–7.PubMedCrossRefGoogle Scholar
  42. 42.
    McNulty C, Logan M, Donald IP, et al. Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy. J Antimicrob Chemother. 1997;40:707–11.PubMedCrossRefGoogle Scholar
  43. 43.
    Carling P, Fung T, Killion A, et al. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol. 2003;24:699–706.PubMedCrossRefGoogle Scholar
  44. 44.
    Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45:302–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005;40:1591–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005;40:1586–90.PubMedCrossRefGoogle Scholar
  47. 47.
    Gerding DN. Metronidazole for Clostridium difficile-associated disease: is it okay for mom? Clin Infect Dis. 2005;40:1598–600.PubMedCrossRefGoogle Scholar
  48. 48.
    Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med. 2006;145:758–64.PubMedGoogle Scholar
  49. 49.
    Maroo S, Lamont JT. Recurrent Clostridium difficile. Gastroenterology. 2006;130:1311–6.PubMedCrossRefGoogle Scholar
  50. 50.
    Karas JA, Enoch DA, Aliyu SH. A review of mortality due to Clostridium difficile infection. J Infect. 2010;61:1–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Garey KW, Sethi S, Yadav Y, et al. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect. 2008;70:298–304.PubMedCrossRefGoogle Scholar
  52. 52.
    Jodlowski TZ, Oehler R, Kam LW, et al. Emerging therapies in the treatment of Clostridium difficile-associated disease. Ann Pharmacother. 2006;40:2164–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364:422–31.PubMedCrossRefGoogle Scholar
  54. 54.
    Miller M. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection. Expert Opin Pharmacother. 2010;11(9):1569–78.PubMedCrossRefGoogle Scholar
  55. 55.
    Persky SE, Brandt LJ. Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. Am J Gastroenterol. 2000;95:3283–5.PubMedGoogle Scholar
  56. 56.
    van Nispen Tot Pannerden CM, Verbon A, Kulpers EJ. Recurrent Clostridium difficile infection: what are the treatment options? Drugs. 2011;71(7):853–68.PubMedCrossRefGoogle Scholar
  57. 57.
    Cheng AC, Ferguson JK, Richards MJ, et al. Australasian Society for Infectious Diseases guidelines for the diagnosis and treatment of Clostridium difficile infection. Med J Aust. 2011;194:353–8.PubMedGoogle Scholar
  58. 58.
    Cohen SH, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare (SHEA) Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–55.PubMedCrossRefGoogle Scholar
  59. 59.
    Longo WE, Mazuski JE, Virgo KS, et al. Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum. 2004;47:1620–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Koss K, Clark MA, Sanders DS, et al. The outcome of surgery in fulminant Clostridium difficile colitis. Colorectal Dis. 2006;8:149–54.PubMedCrossRefGoogle Scholar
  61. 61.
    Surawicz CM. Does emergency colectomy reduce mortality in patients with Clostridium difficile-associated disease? Nat Clin Pract Gastroenterol Hepatol. 2007;4:542–3.PubMedCrossRefGoogle Scholar
  62. 62.
    Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000;31:1012–7.PubMedCrossRefGoogle Scholar
  63. 63.
    McPherson S, Rees CJ, Ellis R, et al. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum. 2006;49:640–5.PubMedCrossRefGoogle Scholar
  64. 64.
    Aboudola S, Kotloff KL, Kyne L, et al. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun. 2003;71:1608–10.PubMedCrossRefGoogle Scholar
  65. 65.
    Voelker R. Increased Clostridium difficile virulence demands new treatment approach. JAMA. 2010;303:2017–8.PubMedCrossRefGoogle Scholar
  66. 66.
    Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010;362:197–205.PubMedCrossRefGoogle Scholar
  67. 67.
    Kyme L. Clostridium difficile—beyond antibiotics. N Engl J Med. 2010;362:264–5.CrossRefGoogle Scholar
  68. 68.
    Vrtis MC. The Clostridium difficile epidemic: a potential disaster for long term care. Ann Long Term Care. 2008;16(7):19–24.Google Scholar
  69. 69.
    Guerrero DM, Nerandzic MM, Jury LA, et al. Clostridium difficile infection in a department of Veterans Affairs long-term care facility. Infect Control Hosp Epidemiol. 2011;32:513–5.PubMedCrossRefGoogle Scholar
  70. 70.
    Lanzas C, Dubberke ER, Lu Z, et al. Epidemiological model for Clostridium difficile transmission in healthcare settings. Infect Control Hosp Epidemiol. 2011;32:553–61.PubMedCrossRefGoogle Scholar
  71. 71.
    Linsky A, Gupta K, Lawler EV, et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med. 2010;170(9):772–8.PubMedCrossRefGoogle Scholar
  72. 72.
    Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol. 2011;8(1):17–28.PubMedCrossRefGoogle Scholar
  73. 73.
    Gerding DN, Johnson S. Advances in pathogenesis, diagnosis and management of CDI. Clostridium difficle infection in 2010. Nat Rev Gastroenterol Hepatol. 2011;8:67–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Doernberg SB, Winston LG, Deck DH, Chambers HF. Does doxycycline protect against development of Clostridium difficile infection? Clin Infect Dis. 2012 May 4; ahead of print.PubMedCrossRefGoogle Scholar
  75. 75.
    Rebeaud F, Bachmann MF. Immunization strategies for Clostridium difficile infections. Expert Rev Vaccines. 2012;11(4):469–79.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • C. S. Pitchumoni
    • 1
  • C. S. Pitchumoni
    • 2
  • C. S. Pitchumoni
    • 3
  • T. S. Dharmarajan
    • 4
  • T. S. Dharmarajan
    • 5
  • T. S. Dharmarajan
    • 6
  • T. S. Dharmarajan
    • 7
  1. 1.Robert Wood Johnson School of Medicine, Drexel University School of MedicinePhiladelphiaUSA
  2. 2.New York Medical CollegeVallhalaUSA
  3. 3.Gastroenterology, Hepatology and NutritionSaint Peter’s University HospitalNew BrunswickUSA
  4. 4.New York Medical CollegeValhallaUSA
  5. 5.Department of MedicineMontefiore Medical Center (North Division)BronxUSA
  6. 6.Division of GeriatricsMontefiore Medical Center (North Division)BronxUSA
  7. 7.Geriatric Medicine Fellowship ProgramMontefiore Medical Center (North Division)BronxUSA

Personalised recommendations